Biologists have long wondered if mammals share the elegant system used by insects, bacteria and other invertebrates to defend against viral infection. Two back-to-back studies in the journal Science last year said the answer is yes, but a study just published in Cell Reports by researchers at the Icahn School of Medicine at Mount Sinai found the opposite.
In the Mount Sinai study, the results found that the defense system used by invertebrates — RNA interferences or RNAi — is not used by mammals as some had argued. RNAi are small molecules that attach to molecular scissors used by invertebrates to cut up invading viruses.
Mammals use a form of RNAi to fine-tune the expression of hundreds of genes that coordinate development in the womb, says the study's senior author, Benjamin tenOever, PhD, Fishberg Professor in the Department of Medicine and Department of Microbiology at the Icahn School of Medicine at Mount Sinai. But it has never been clear that adult mammals use RNAi the same way that plants and insects do, he says. "Mammals have cell machinery that looks capable of producing RNAi to fight virus, but we believe it only helps to produce different small RNA products called microRNAs, which are not antiviral," Dr. tenOever says.
The correct answer matters because RNAi is being studied as a potential basis for new kinds of drugs for the treatment of hemophilia, beta-thalassemia and many viral infections, says Dr. tenOever.
"We believe our results settle a longstanding debate about whether mammals, including humans and mice, fight viruses using RNAi, and the answer is good news," he says. "Drug designers interested in using RNAi to treat disease have worried that if RNAi is part of the mammalian response to viral infections, RNAi-based agents could compromise a human's immune response, producing unintended consequences. That is not a concern now, based on our findings."
Mammals are known to fend off viruses with a system based on interferons, signaling proteins made by immune cells that amplify the body's attack on invaders. The finding that mammals do not use RNAi to fight viruses suggests that RNAi-based drugs could augment the existing interferon response in mammals, Dr. tenOever says. "We could harness this potent RNAi viral-killing machine when natural human immunity isn't enough."
To answer the question, a team of researchers from the Icahn Graduate School of Biomedical Science used a virus that produces oral lesions in cows and pigs. They eliminated the part of the virus that causes disease, rendering it harmless and susceptible to both RNAi and interferons. They then took this harmless virus and gave it the capacity to block either interferon or RNAi.
In experiments with mice, when the virus was designed to block interferon, no immune defense occurred and the interferon-blocking virus flourished. In contrast, giving the virus the capacity to block RNAi, found that the animals mounted a robust interferon-based defense that further weakened the RNAi-blocking virus. The same thing happened when the RNAi-blocking virus was introduced to engineered mice that could not produce interferons. "If mammals used interferon and RNAi to fight the virus, we would have seen the RNAi-blocking virus flourish in at least this setting — but we did not," Dr. tenOever says. "This is the strongest published data that argues against recent claims that RNAi exists in mammals, he says.
Study co-authors include Mount Sinai researchers Simone Backes, PhD, Ryan Langlois, PhD, Sonja Schmid, PhD, Andrew Varble, PhD, Jaehee Shim and David Sachs. The study was supported in part by the U.S. Army Research Laboratory and the U.S. Army Research Office under grant numbers W911NF-12-R-0012 and W911NF-07-R-0003.
About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven member hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community‐based facilities to tertiary and quaternary care.
The System includes approximately 6,600 primary and specialty care physicians, 12‐minority‐owned free‐standing ambulatory surgery centers, over 45 ambulatory practices throughout the five boroughs of New York City, Westchester, and Long Island, as well as 31 affiliated community health centers. Physicians are affiliated with the Icahn School of Medicine at Mount Sinai, which is ranked among the top 20 medical schools both in National Institutes of Health funding and by U.S. News & World Report.
For more information, visit http://www.mountsinai.org, or find Mount Sinai on Facebook, Twitter and YouTube.
Greg Williams | Eurek Alert!
Cohesin down-regulation drives hematopoietic stem cell aging
14.12.2018 | Leibniz-Institut für Alternsforschung - Fritz-Lipmann-Institut e.V. (FLI)
Magic number colloidal clusters
13.12.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
What if a sensor sensing a thing could be part of the thing itself? Rice University engineers believe they have a two-dimensional solution to do just that.
Rice engineers led by materials scientists Pulickel Ajayan and Jun Lou have developed a method to make atom-flat sensors that seamlessly integrate with devices...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Ecology, The Environment and Conservation
13.12.2018 | Life Sciences
13.12.2018 | Physics and Astronomy